Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes.
IC50&Target
Glucokinase
体内研究
Dorzagliatin (low-dose 10 mg/kg, and high-dose 30 mg/kg; administered intragastrically; daily 8:00 AM for one month) exerts a glucose-lowering effect on the glucose levels in diabetic rats.